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Abstract 
Background: Wolcott-Rallison Syndrome is a rare autosomal recessive disorder 
characterized by neonatal/early-onset non-autoimmune insulin-dependent diabetes, 
multiple epiphyseal dysphasia and growth retardation. It is caused by mutations in the 
gene encoding eukaryotic translation initiation factor 2α kinase 3 (EIF2AK3). We 
aimed to study the clinical characteristics and frequency of the disease in the Iranian 
population.  
Method: We recruited 42 patients who referred to the endocrine and metabolism clinic 
at Mashhad Imam Reza Hospital with neonatal diabetes. Molecular screening of 
KCNJ11, INS, ABCC8 and EIF2AK3 was performed at the Exeter Molecular Genetics 
Laboratory, UK. We calculated the frequency of the disease in 124 patients referred 
from Iran to the Exeter Molecular Genetics Laboratory for genetic screening and 
compared it to other countries worldwide. 
Results: We identified 7 patients as having Wolcott-Rallison Syndrome. The genetic 
testing confirmed the clinical diagnosis and indicated five novel mutations. Only 2 
patients developed clinical features of the syndrome by 6 months of age. Of all 124 
cases of Iranian neonatal diabetes referred to the Exeter Molecular Genetics Laboratory 
for genetic screening, 28 patients (22.58%) had a recessive mutation in EIF2AK3. 
Conclusion: The results of this study raises awareness of the condition and provides 
further accurate data on the genetic and clinical presentation of Wolcott-Rallison 
Syndrome in the Iranian population. Our study highlights the importance of genetic 
testing in patients from consanguineous families with diabetes diagnosed within the 
first 6 months of life.  
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Introduction: 
Permanent neonatal diabetes mellitus (PNDM) diagnosed before 6 months of age is 
mainly monogenic rather than autoimmune (1, 2) and affects approximately one in 
100,000 live births (3). The majority of patients have heterozygous mutations in the 
KCNJ11 and ABCC8 genes or the pre-proinsulin (INS) gene (4-9). However, in patients 
born to related parents, homozygous mutations in EIF2AK3 are the most common cause 
of neonatal diabetes (10). EIF2AK3 is located on chromosome 2p1 and encodes 
eukaryotic translation initiation factor 2α kinase 3 also known as PKR-like endoplasmic 
reticulum kinase (PERK). Functional studies have shown that Perk is essential for 
neonatal development of β cells and that loss of PERK expression in β cells reduces β 
cell mass and insulin secretion leading to neonatal diabetes independently of an 
autoimmune process(11). Homozygous mutations in EIF2AK3 cause a syndrome called 
Wolcott-Rallison Syndrome characterized by neonatal non-autoimmune insulin-
dependent diabetes, multiple epiphyseal dysphasia and growth retardation (12).  
The clinical diagnosis of Wolcott-Rallison syndrome requires the presence of 
permanent neonatal diabetes associated with skeletal dysplasia and/or episodes of acute 
liver failure (12). Although diabetes in these patients is often diagnosed within the first 
6 months of life, the key presenting features of the syndrome, including skeletal 
dysplasia and liver failure, can appear later during the course of the disease. Other 
clinical findings of a different nature and severity include renal dysfunction, pancreatic 
exocrine failure, neutropenia, recurrent infections, hypothyroidism, intellectual deficit, 
and bone fractures (12). The disease is thought to be underdiagnosed due to the deaths 
of patients prior to the appearance of the full spectrum of clinical manifestations. Early 
diagnosis of Wolcott-Rallison syndrome is of great value in predicting complications 
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and timely intervention in life-threatening episodes of liver failure. In contrast to other 
forms of diabetes, insulin treatment should not target a tight control of blood glucose 
as hypoglycemia could trigger episodes of acute aggravation of the disease(12). 
Since familial marriage is common in Iran (37.4%) (13), Wolcott-Rallison syndrome is 
probably one of the more important causes of PNDM. We present here the clinical 
spectrum of this syndrome in 7 patients with a genetic diagnosis of Wolcott-Rallison 
syndrome and highlight the importance of genetic testing in patients from 
consanguineous families with diabetes diagnosed within the first 6 months of life.  
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Materials and methods 
Patients  
We recruited 42 patients with diabetes diagnosed before the age of 6 months who were 
referred to the Imam Reza Hospital, Mashhad University of Medical Science. We 
obtained written consent for clinical and genetic investigation from the patients’ parents 
or their legal guardians. Clinical information was collected at the time of referral. 
Parental consanguinity was defined as parents being first or second cousins. The study 
was approved by the ethics committee of the Mashhad University of Medical Science.  
Genetic analysis 
Peripheral blood samples were collected from affected patients and their parents to 
extract DNA using standard procedures. Molecular screening of KCNJ11, INS, ABCC8 
and EIF2AK3 was performed at the Exeter Molecular Genetics Laboratory, UK 
(http://www.diabetesgenes.org/content/genetic-testing-neonatal-diabetes). The coding 
and flanking intronic regions of the genes were analyzed by PCR followed by Sangers 
sequencing. Sequences were compared with the published template (NM_000525, 
NM_000207, NM_000352.2 and AF110146.1).  
We checked the frequency of the identified variants in GnomAD (>120,000 
individuals; http://gnomad.broadinstitute.org) and in human variant and mutation 
databases, such as ClinVar and Human Gene Mutation Database, as well as the relevant 
literature. We used the bioinformatics tools SIFT, PolyPhen-2 and Align GVGD which 
were accessed through the ALAMUT Visual software version 2.7.1 (Interactive 
Biosoftware, Rouen, France) to predict the effect of novel variants. Rare variants were 
tested for their presence in parents. 
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Statistical analysis 
Clinical numeric data are given as median and interquartile range (IQR). We used the 
Chi-square test to assess the differences between the consanguineous and non-
consanguineous groups. 
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Results 
We identified seven new cases of Wolcott-Rallison Syndrome in North-East of 
Iran. 
Of the 42 patients with neonatal diabetes, homozygous likely pathogenic and 
pathogenic EIF2AK3 variants confirming a genetic diagnosis of Wolcott-Rallison 
syndrome were identified in 7 patients. Five novel mutations were detected: 
c.1745_1746del (p.Ser582fs), c.733dup (p.Arg245fs), c.1149_1150del (p.Asn383fs), 
c.869_870del (p.Glu290fs) and c.536C>A (p.Ser179*) (table 1). All parents were 
heterozygous carriers. 
The median age at diagnosis of diabetes in patients with a mutation in EIF2AK3 was 3 
months (interquartile range (IQR) [2–6]) whilst the median age at diagnosis in the 35 
patients without an EIF2AK3 mutation was 2 months (IQR [1–5]). The median birth 
weight was 2,970 grams (IQR [2,470–3,375]) which was higher than in patients who 
did not have mutation in EIF2AK3 (1650 grams [1650-3150]), although this difference 
was not statistically significant (pdifference > 0.05). The consanguinity rate in patients 
with mutations in EIF2AK3 was 100% compared to 57% in the rest of the cohort 
(pdifference = 0.03). Full clinical description of patients is included in the supplementary 
note. 
Case 1 was hospitalized at the age of 2 months with metabolic acidosis, hyperglycemia, 
elevated hepatic enzymes, hepatomegaly, renal dysfunction and spastic seizures. 
Currently she is 6 years old with severe neuromotor deficit, microcephaly and evident 
skeletal dysplasia, short trunk, kyphosis and genu valgum (figure 1). In her X-ray 
radiographies, we observed generalized osteoporosis, bilateral hip dislocation, delay in 
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bone age and epiphyseal dysplasia at radius end (figure 2). The CT scan revealed 
bilateral calcifications of basal ganglions (figure 3). She is homozygous for 
c.1745_1746del mutation.  
Case 2 was hospitalized at age 54 days with edema and jaundice. Laboratory findings 
included elevated hepatic enzymes and direct hyperbilirubinemia. Hepatic biopsy 
revealed a hyperplasic biliary duct and sedimentation of large amounts of biliary 
pigments with no fibrosis. Currently he is 9 years old. He has mild intellectual 
disability. Clinical examination showed bilateral genu valgum. Bilateral hemi-
epiphyseal of femur and proximal of tibia is evident in radiographic examination. He is 
homozygous for c.733dup mutation.  
Case 3 was hospitalized for respiratory distress and fever at age 2 months after 
vaccination and diabetic ketoacidosis (DKA). The patient had cleft lip. Currently he is 
9 years old with severe intellectual disability. His skeletal disorders include pigeon 
chest, genu valgum and short trunk. His condition resembles Mucopolysaccharidosis 
type IV though enzymatic test excluded Mucopolysaccharidosis type I, IV and VI and 
no progressive skeletal dysplasia was detected in his skeletal X-rays at 6 years old. He 
is homozygous for c.1149_1150del mutation. 
Case 4 was hospitalized with fever and lethargy at the age of 2 months and diagnosed 
with DKA. She was admitted again at age of 8 months for edema and jaundice and 
showed hepatic cholestatic failure. Currently she is 10 years old with mild intellectual 
disability. She has severe motor limitations and skeletal deformities with short trunk, 
kyphosis and genu valgum. She is homozygous for c.869_870del mutation. 
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Case 5 was hospitalized due to fever and restlessness at age 20 days. He had a history 
of recurrent infections during the first year of life. He underwent bilateral surgery due 
to undescended testes at the age of 1 year. He is currently 24 months old. Generalized 
osteoporosis, epiphytical digenesis at femur ends and proximal of tibia, and bilateral 
dislocation of hip were evident in his radiography. The patient had motor 
developmental delay but mentally was within normal range. He is homozygous for 
c.536C>A mutation. 
Case 6 presented with DKA at 6 months. At 7 months, she was admitted to the hospital 
with effusion in the right knee joint and septic arthritis. Culture of the synovial fluid 
grew pseudomonas aeruginosa. Currently she is 21 months with mild cognitive and 
motor delays. She has short trunk and bilateral genu valgus deformity. Skeletal survey 
revealed epiphyseal dysplasia involving proximal and distal femoral epiphysis and 
proximal tibial epiphysis, generalized osteoporosis, thoracic kyphosis and lumbar 
lordosis and mild platyspondyly. At the pelvic level, epiphyses are flattened with coxa 
vara (figure 4). She is homozygous for c.1149_1150del mutation. 
Case 7 presented with DKA at 6 months. At 4 years old, after a common cold and fever, 
hepatic involvement presented with icterus and hepatomegaly and spontaneously 
resolved after 2-3 weeks. Currently, he is 6.5 years old. He has mild intellectual 
disability. He has kyphosis and genu valgus deformity. He is homozygous for 
c.536C>A mutation. 
One out of four patients with neonatal diabetes from consanguineous parents have 
mutation in EIF2AK3.  
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We used the Exeter Neonatal Diabetes cohort to calculate the frequency of mutations 
in EIF2AK3 in patients referred from Iran. A total of 124 patients with neonatal diabetes 
below age of 6 months have been referred to the Exeter Molecular Genetics Laboratory 
for genetic testing. The diagnostic genetic test identified a homozygous mutation in 
EIF2AK3 for 28 patients (22.58%); among them 22 patients (78.57%) were reported to 
be born to consanguineous parents. We excluded the patients who were not known to 
be born to related parents or for whom data was missing. Of 77 children who were from 
consanguineous families, 22 patients (28.57%) had a recessive mutation in EIF2AK3. 
In contrast to neonatal diabetes in Europeans, mutations in KCNJ11, ABCC8 and INS 
altogether accounted for only 31% of neonatal diabetes cases in 124 Iranian patients. 
To compare the frequencies with other ethnicities, we investigated 999 cases of 
neonatal diabetes referred from 83 countries for genetic diagnostic test. Country of 
referral was missing in 7 patients. We divided patients into 14 geographical regions 
based on the country of referral including Asia, South Asia, East Asia, Middle East, 
Eurasia, Europe, Australia, East Africa, South Africa, North Africa, North America, 
South America, Central America and the Caribbean (table 2). The recessive mutations 
in EIF2AK3 were most prevalent in North Africa (28.12% of 32 referrals), Middle East 
(18.5% of 173 referrals), and South Asia (15.22 % of 92 referrals). In contrast, the 
frequency of genetically diagnosed Wolcott-Rallison Syndrome was 6.12% (total 
number of referred samples = 49) in Asia, 3.38 % (385) in Europe and 1.02% (97) in 
North America. There were no cases of genetically diagnosed Wolcott-Rallison 
Syndrome in samples referred from Australia (39 patients), East Asia (19 patients), 
South America (58 patients), South Africa (26 patients), Central America (12 patients), 
Eurasia (2 patients), East Africa (3 patients) and the Caribbean (6 patients).  
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Discussion: 
We reported 7 new cases of Wolcott-Rallison Syndrome from the north east of Iran 
identified by genetic testing. These patients had 5 novel homozygous mutations.  Our 
study provides evidence that Wolcott-Rallison Syndrome is a common cause of 
neonatal diabetes in Iran. Among 124 neonatal diabetes patients referred to the Exeter 
Molecular Genetics Laboratory from Iran, 22.58% had a homozygous mutation in 
EIF2AK3. The prevalence of neonatal diabetes due to mutations in EIF2AK3 was 
similar to countries where the rate of consanguinity is high, including countries in North 
Africa (28.12% of neonatal diabetes), Middle East (18.5% of neonatal diabetes) and 
South Asia (15.22% of neonatal diabetes).  
Insulin dependent non-autoimmune diabetes is a cardinal feature of Wolcott-Rallison 
Syndrome; the median age of incident of diabetes has been reported as 10.5 weeks with 
the earliest age of presentation at 3 weeks (14). In all but two patients, diabetes was 
diagnosed within the first 6 months of life although there are 2 cases where diabetes 
was diagnosed at ages of 14 and 30 months (14, 15). There is no reported association 
between different types of mutation and age of presentation of diabetes (10). In our 
study, 4 patients presented with diabetes at approximately age 2 months, one patient 
was diagnosed at the age of 20 days and one at age of 6 months.  
Although patients with Wolcott-Rallison Syndrome have a lower birth weight than the 
population (median -1.4 standard deviation score), low birth weight (<2500 grams) is 
not common (10). In our study, 5 cases had a birth weight lower than 3000 grams 
including 2 patients with low birth weight (<2500 grams). There was no significant 
correlation between birth weight and age at diagnosis of diabetes; consistent with 
previous studies (10).  
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Skeletal involvement characterized with multiple epiphiseo-metaphyseal dysplasia 
usually affects long bones, the pelvis and vertebrae without affecting the skull, and 
usually is detected between the ages of 1 and 2 years (12, 16). Skeletal deformities in 
all 4 patients in the present study, who are currently 6-10 years old, are evident in form 
of short trunk, kyphosis, pigeon chest, genu valgum and abnormal gait. Although 
evidence of skeletal deformities are currently not present in case 5 who is only 2 years 
old, delayed walking, short height and abnormal gait are evident. 
Osteoid odontoideum in which the odontoid peg separates radiologically from the 
second cervical vertebra is common in patients with Wolcott-Rallison Syndrome. This 
condition can be clinically asymptomatic or associated with spinal cord compression 
symptoms even in transient form. It is recommended that all patients suffering Wolcott-
Rallison Syndrome undergo regular appropriate evaluation for Os odontoideum 
screening including imaging (17). There was no evident of cord compression in 
neurological assessments of our patients although imaging was not performed. 
Hepatic diseases are characteristic findings of Wolcott-Rallison Syndrome (10, 12). 
Hepatic involvement in the form of cholestasis, jaundice, higher levels of hepatic 
enzymes or hepatomegaly were detected in 3 patients in this study; 2 patients presented 
hepatic involvement at the time diabetes was diagnosed. This included elevated hepatic 
enzymes associated with hepatomegaly in case 1 and elevated hepatic enzymes and 
direct hyperbilirubinemia in case 2. 
Intellectual disability and developmental delay, with a range of different severities, are 
very common in Wolcott-Rallison Syndrome patients (15). In our study, 4 cases 
developed neuromotor retardation and case 5 had developmental delay. Various central 
nervous system anomalies including cerebellar cortical dysplasia, microcephaly, 
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cerebral atrophy, pachygyria and cerebellar hypoplasia have been described in patients 
with Wolcott-Rallison Syndrome (18, 19). 
Bilateral calcification of basal ganglion in one of the patients (case 1), who is under 
treatment for epilepsy, was reported for the first time. Case 1 in this study also 
underwent peritoneal dialysis due to a rise in blood urea nitrogen and creatinine; renal 
function was recovered almost immediately. Other clinical futures including 
hypothyroidism, neutropenia and exocrine pancreas insufficiency were not seen in our 
patients.  
Many cases of Wolcott-Rallison Syndrome die before complete clinical presentation of 
the disease appears.  Cases of Wolcott-Rallison Syndrome can develop variable clinical 
phenotypes starting at different time points after the initial diabetes diagnosis, causing 
many cases to be either misdiagnosed or undiagnosed. The most common implications 
include skeletal dysplasia and liver failure which is the most deadly feature of the 
disease. To prepare for right clinical intervention and management of the disease, a 
timely diagnosis is critical. 
Wolcott-Rallison Syndrome is a common cause of neonatal diabetes in Iran due to the 
high rate of consanguineous marriage. Many cases of Wolcott-Rallison Syndrome 
might remain undiagnosed. We recommend genetic testing for all cases of neonatal 
diabetes born to consanguineous parents worldwide to be undertaken at the time of 
diagnosis, to predict the best available diabetes treatment and allow anticipation of the 
development of related features.   
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Figure 1: Skeletal dysplasia and growth retardation in proband 1 (age 6 years). 
The patient has evident skeletal dysplasia, short trunk, kyphosis and genu valgum. 
Figure 2: Radiographs of proband 1. (A) Pelvis: the acetabular roofs are hypoplastic 
with dysplastic capital femoral epiphyses. (B) Spine: dorsal region of spine shows 
flattening of the vertebral bodies with defects at the anterior edges and sever 
osteoporosis. (C) Hand:  dysplasia in distal radius and ulna epiphyses; several 
phalanges are dysplastic with abnormal metaphyseal cupping at the proximal ends. 
Figure 3: CT scan of brain in proband 1. The patient has bilateral calcifications of 
basal ganglions. 
Figure 4: Radiographs of proband 7. (A) Short trunk, kyphosis, and bilateral genu 
valgus deformity. (B) Epiphyseal dysplasia involving proximal and distal femoral 
epiphysis and proximal tibial epiphysis. (C) At the pelvic level, epiphyses are flattened 
with coxa vara. 
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Table 1. Mutation description and phenotype of study participants. 
Individual  Mutation 
description  
Age of 
Diagnosis 
(months) 
Gestational 
age 
(weeks) 
Birth 
weight 
(grams) 
Sex Current 
age 
(years) 
Current weight 
Kg (Z-score) 
Current height 
cm (Z-score) 
Reported features  
Case 1 p.Ser582fs  2 39 2250 F 6 11 (-5.1) 100 (-3.2) Microcephaly, hypotonia, absence of head control, 
leukodistrophy, liver disease, renal disease, seizure, 
skeletal anomalies 
Case 2 p.Arg245fs 2 37 2460 M 9 13 (-6) 
 
89 (-8.1) liver disease, skeletal anomalies, developmental 
delay 
Case 3 p.Asn383fs  2 38 2900 M 9 14.2 (-5.6) 98 (-6.3) 
 
Intellectual disability, skeletal anomalies 
Case 4 p.Glu290fs 2 36 2780 F 10 17.5 (-3) 110 (-4.5) Intellectual disability, skeletal anomalies, liver 
disease 
Case 5 p.Ser179*  1 39 
 
3200 M 2 9.5 (-2) 76 (-3.7) developmental delay, recurrent infections, skeletal 
anomalies 
Case 6 p.Asn383fs  6 40 2740 F 2 9.9 (-0.2) 81 (-0.4) Pseudomonas infections in knees, arthritis, skeletal 
anomalies, developmental delay 
Case 7 p.Ser179*  6 41 3550 M 6.5 23 (0.6) 112 (-1.3) Skeletal anomalies, liver disease 
F: female; M: male; del: deletion; fs: frameshift. The * symbol indicates a Stop codon. 
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Table 2. The frequencies of recessive mutations in EIF2AK3 in 999 cases of neonatal 
diabetes referred from 83 countries for genetic diagnostic test to the Exeter Molecular 
Genetics Laboratory. We divided patients into 14 geographical regions based on the 
country of referral including. We did not have information on country of referral for 7 
patients. 
Geographical regions Patients with recessive 
mutations in EIF2AK3  
n (%) 
Total number 
of referrals 
Countries (number of referrals)  
North Africa 9 (28.12%) 32 Egypt (9), Libya (6), Morocco (8), Sudan 
(8) and Tunisia (1) 
Middle East 32 (18.5%) 173 Bahrain (2), Iraq (2), Israel (6), Jordan 
(16), Kuwait (8), Lebanon (1), Oman (8), 
Qatar (1), Saudi Arabia (34), Syria (1), 
Turkey (80), UAE (14) 
South Asia 14 (15.22 %) 92 Bangladesh (10), India (75), Pakistan (7) 
Asia 3 (6.12%) 49 Malaysia (9), Singapore (5), Thailand 
(5), Vietnam (29), Philippines (1) 
Europe 13 (3.38 %) 385 Austria (10), Belgium (8), Bulgaria (4), 
Czech Republic (12), Denmark (3), 
France (5), Germany (82), Hungary (5), 
Bosnia (1), Croatia (3), Cyprus (2), 
Finland (1), Greece (3), Ireland (8), 
Netherlands (24), Kosovo (1), Latvia (3), 
Macedonia (2), Poland (20), Portugal (2), 
Romania (1), Serbia (3), Slovakia (8), 
Spain (5), Sweden (17), Switzerland (3), 
UK (142), Ukraine (7) 
North America 1 (1%) 97 US (68), Canada (29) 
Australia and New Zealand 0 (0%) 39 New Zealand (11), Australia (28) 
East Asia 0 (0%) 19 China (14), Japan (4), Republic of Korea 
(1) 
Eurasia 0 (0%) 2 Russia (1), Georgia (1) 
East Africa 0 (0%) 3 Kenya (2), Mauritius (1) 
South Africa 0 (0%) 26 South Africa (26) 
Central America 0 (0%) 11 Costa Rica (5), Guatemala (1), Honduras 
(4), Mexico (1) 
South America 0 (0%) 58 Argentina (20), Brazil (7), Chile (15), 
Colombia (1), Peru (1), Venezuela (14) 
The Caribbean 0 (0%) 6 Puerto Rico (5), Trinidad and Tobago (1) 
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